Also, according to the Yale analysis, top executives at three other patient advocacy groups—Michael J. Fox Foundation for Parkinson’s Research, the Cancer Research Institute, and the Foundation Fighting Blindness—were serving simultaneously on pharmaceutical boards: Pfizer, Coherus BioSciences, and Opus Genetics.
